

Receipt date: 06/13/2008

10599976 - GAU: 1654

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 12

ATTORNEY DOCKET NO.

SERIAL NO.

6102-000049/US/NP

10/599,976

APPLICANT

Scheller, D. & Stoehr, T.

FILING DATE

GROUP

October 16, 2006

1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/Subclass	Filing Date
L1		4,303,673	Dec 1, 1981	Biedermann <i>et al.</i>	424/324	
L2		4,510,082	Apr 9, 1985	Gesellchen & Shuman	260/112.5R	
L3		4,513,009	Apr 23, 1985	Roques <i>et al.</i>	514/513	
L4		4,533,657	Aug 6, 1985	Morgan	514/19	
L5		4,618,708	Oct 21, 1986	Roques <i>et al.</i>	562/448	
L6		4,707,468	Nov 17, 1987	Yoshino <i>et al.</i>	514/16	
L7		5,378,729	Jan 3, 1995	Kohn & Watson	514/231.2	
L8		5,508,266	Apr 16, 1996	Fink	514/19	
L9		5,536,853	Jul 16, 1996	Spellmeyer <i>et al.</i>	549/441	
L10		5,656,267	Aug 12, 1997	Sagen & Pappas	424/93.21	
L11		5,760,038	Jun 2, 1998	Murugesan <i>et al.</i>	514/252	
L12		5,773,475	Jun 30, 1998	Kohn	514/616	
L13		5,780,589	Jul 14, 1998	Lazarus <i>et al.</i>	530/331	
L14		5,866,585	Feb 2, 1999	Fogel	514/289	
L15		5,885,999	Mar 23, 1999	Elliott <i>et al.</i>	514/258	
L16		6,001,876	Dec 14, 1999	Singh	514/561	
L17		6,028,102	Feb 22, 2000	Bialer <i>et al.</i>	514/489	Feb 24, 1998
L18		6,037,324	Mar 14, 2000	Schwender & Shroff	514/18	Jan 4, 1996
L19		6,083,941	Jul 4, 2000	Farb	514/177	Jul 24, 1996
L20		6,083,951	Jul 4, 2000	Bradbury	514/256	Dec 14, 1998
L21		6,103,732	Aug 15, 2000	Amberg <i>et al.</i>	514/269	Apr 4, 1997
L22		6,114,390	Sep 5, 2000	Engel <i>et al.</i>	514/595	Oct 14, 1997
L23		6,126,939	Oct 3, 2000	Eisenbach-Schwartz <i>et al.</i>	424/185.1	May 28, 1997
L24		6,180,611	Jan 30, 2001	Montana <i>et al.</i>	514/19	May 20, 1999
L25		6,277,825	Aug 21, 2001	Olivera <i>et al.</i>	514/13	Jul 20, 1999
L26		6,737,408	May 18, 2004	Balasubramaniam <i>et al.</i>	514/18	Jul 18, 2000
L27		2003/0216466	Nov 20, 2003	Scheuerman <i>et al.</i>	514/513	May 13, 2003

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 327048892 US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 12	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/Subclass	Filing Date
L28		2004/0101582	May 27, 2004	Wolicki	424/760	Nov 25, 2002
L29		2005/0013856	Jan 20, 2005	Trivedi & Gokhale	424/464	Dec 18, 2003
L30		2005/0043675	Feb 24, 2005	Pastore <i>et al.</i>	604/67	Aug 21, 2003
L31		2005/0227961	Oct 13, 2005	Kucharik & Speicher	514/211.13	Nov 30, 2004
L32		2005/0261204	Nov 24, 2005	Stoehr	514/19	May 16, 2005
L33		2005/0277596	Dec 15, 2005	Stoehr	514/19	Jun 7, 2005
L34		2005/0288234	Dec 29, 2005	Stoehr	514/19	Jun 10, 2005
L35		2006/0009384	Jan 12, 2006	Rudd & Stoehr	514/12	Dec 3, 2004
L36		2006/0046957	Mar 2, 2006	Beyreuther & Stoehr	514/7	Aug 26, 2005
L37		2006/0135437	Jun 22, 2006	Stoehr & Rausschkolb-Loeffler	514/19	Jun 9, 2005

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/Subclass	Translation Yes	No
L38		DE 195 33 023	Apr 18, 1996	Germany	C07D 239/60	X	
L39		EP 0 555 537	Aug 18, 1993	EPO	C07K 5/06		
L40		EP 0 997 147	May 3, 2000	EPO	A61K 31/165		
L41		EP 1 243 263	Nov 27, 2002	EPO	A61K 31/165		
L42		EP 1 486 205	Dec 15, 2004	EPO	A61K 31/16		
L43		EP 1 486 206	Dec 15, 2004	EPO	A61K 31/16		
L44		EP 1 537 862	Jun 8, 2005	EPO	A61K 31/165		
L46		EP 1 541 138	Jun 15, 2005	EPO	A61K 31/165		
L46		EP 1 579 858	Sep 28, 2005	EPO	A61K 31/165		
L47		EP 1 688 137	Aug 9, 2006	EPO	A61K 31/165		
L48		WO 92/14706	Sep 3, 1992	WIPO	C07D 207/16		
L49		WO 95/30645	Nov 16, 1995	WIPO	C07C 233/11		
L50		WO 96/11209	Apr 18, 1996	WIPO	C07K 5/06		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. /

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 3 of 12	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/Subclass	Translation	
						Yes	No
L51		WO 96/32100	Oct 17, 1996	WIPO	A61K 31/165		
L52		WO 97/38980	Oct. 23, 1997	WIPO	C07D 239/52	X	
L53		WO 97/38981	Oct. 23, 1997	WIPO	C07D 239/52	X	
L54		WO 98/09953	Mar. 12, 1998	WIPO	C07D 237/52	X	
L55		WO 99/02146	Jan 21, 1999	WIPO	A61K 31/165		X
L56		WO 99/07413	Feb 18, 1999	WIPO	A61K 45/06		
L57		WO 99/16444	Apr 8, 1999	WIPO	A61K 31/505	X	
L58		WO 99/23078	May 14, 1999	WIPO	C07D 239/00	X	
L59		WO 99/43309	Sep 2, 1999	WIPO	A61K 31/00		
L60		WO 00/51586	Sep 8, 2000	WIPO	A61K 31/00		
L61		WO 01/17976	Mar 15, 2001	WIPO	C07D 239/69		
L62		WO 01/78762	Oct 25, 2001	WIPO	A61K 38/22		
L63		WO 02/13766	Feb 21, 2002	WIPO	A61K		
L64		WO 02/15922	Feb 28, 2002	WIPO	A61K 38/00		
L65		WO 02/42256	May 30, 2002	WIPO	C07C 237/06		
L66		WO 02/74297	Sep 26, 2002	WIPO	A61K 31/165		
L67		WO 02/74784	Sep 26, 2002	WIPO	C07K		
L68		WO 02/76979	Oct 3, 2002	WIPO	C07D 403/12		
L69		WO 02/87548	Nov 7, 2002	WIPO	A61K 9/20		
L70		WO 02/88664	Nov 7, 2002	WIPO	G01N		
L71		WO 03/000642	Jan 3, 2003	WIPO	C07C 203/04		
L72		WO 04/014895	Feb 19, 2004	WIPO	C07D 403/04		
L73		WO 04/043926	May 27, 2004	WIPO	C07D 213/64		
L74		WO 04/046178	Jun 3, 2004	WIPO	C07K 14/435		
L75		WO 04/060353	Jul 22, 2004	WIPO	A61K 9/16		
L76		WO 04/066987	Aug 12, 2004	WIPO	A61K 31/00		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 4 of 12	ATTORNEY DOCKET No.	SERIAL No.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/Subclass	Translation Yes No	
L77		WO 04/066990	Aug 12, 2004	WIPO	A61K 31/135		
L78		WO 04/091585	Oct 28, 2004	WIPO	A61K 9/20		
L79		WO 04/100871	Nov 25, 2004	WIPO	A61K		
L80		WO 05/053667	Jun 16, 2005	WIPO	A61K 31/165		
L81		WO 05/092313	Oct 6, 2005	WIPO	A61K 31/165		
L82		WO 05/099740	Oct 6, 2005	WIPO	A61K 38/05		
L83		WO 05/120539	Dec 22, 2005	WIPO	A61K 38/00		

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
L84		Abbott <i>et al.</i> (1995) Pain 60:91-102
L85		Abdulla & Smith (2002) J. Neurophysiol. 88:2518-2529
L86		Akiba <i>et al.</i> (2003) Receptors & Channels 9:291-299
L87		Albensi <i>et al.</i> (2004) Am. J. Alzheimer's Disease & Other Dementias 19:269-274
L88		Amir <i>et al.</i> (2006) J. Pain 7(5 Suppl. 3):S1-S29
L89		Arnér & Meyerson (1988) Pain 33:11-23
L90		Arnt <i>et al.</i> (1984) Pol. J. Pharmacol. Pharm. 36:221-230
L91		Arroyo (2003) "Safety of SPM 927 in subjects with epilepsy and neuropathic pain" Poster presented at AES Scientific Exhibit, December 5-10, 2003
L92		Backonja (2002) Neurology 59:S14-S17
L93		Backonja (2003) Anesth. Analg. 97:785-790
L94		Béguin <i>et al.</i> (2003) Bioorganic & Medicinal Chemistry 11:4275-4285
L95		Béguin <i>et al.</i> (2004) Bioorganic & Medicinal Chemistry 12:3079-3096
L96		Ben-Menachem (2005) "A dose-response, placebo-controlled trial using lacosamide as adjunctive therapy in subjects with partial seizures" Presented at 26th International Epilepsy Congress, Paris, Aug 28 - Sep 1, 2005

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 5 of 12	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
L97		Ben-Menachem <i>et al.</i> (2005) "Efficacy and safety of adjunctive oral lacosamide for the treatment of partial-onset seizures in patients with epilepsy" Poster P03.101 presented at American Academy of Neurology 57th Annual Meeting, Miami Beach, FL
L98		Bennett & Xie (1988) Pain 33(1):87-107 (abstract only http://www.ncbi.nlm.nih.gov/pubmed/2837713)
L99		Bennett <i>et al.</i> (2000) Pain 86:163-175
L100		Beyak <i>et al.</i> (2004) Am. J. Physiol. Gastrointest. Liver Physiol. 287:G845-G855
L101		Beyreuther (2004) "Pharmacology of SPM 927 and its relevance to clinical practice for neuropathic pain" Presented at Visiongain Pain Management, 2004
L102		Beyreuther <i>et al.</i> (2004) "SPM 927 displays potent antinociceptive effects in rat models for inflammatory and neuropathic pain" Poster presented at Neuropathic Pain, May 13-14, 2004
L103		Beyreuther <i>et al.</i> (2005) "Lacosamide displays antinociceptive effects in a rat model for tumor-induced cancer pain and chemotherapy-induced pain" Poster presented at World Congress on Pain, August 21-26, 2005
L104		Beyreuther <i>et al.</i> (2005) "Lacosamide displays antinociceptive effects in a rat model for diabetic neuropathic pain" Presented at World Congress on Pain, August 21-26, 2005
L105		Beyreuther <i>et al.</i> (2006) "Effects of lacosamide as compared to other analgesics: a responder analysis in the streptozotocin rat model for diabetic neuropathic pain" Poster 618 presented at American Pain Society, 2006 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster_id=2637#618)
L106		Beyreuther <i>et al.</i> (2006) "Lacosamide displays antinociceptive effects in a rat model for musculoskeletal pain induced by TNF" Poster 625 presented at American Pain Society, 2006 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster_id=2643#625)
L107		Beyreuther <i>et al.</i> (2006) "Lacosamide displays antinociceptive effects in rat models for arthritis pain" Poster 626 presented at American Pain Society, 2006 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster_id=2644#626)
L108		Beyreuther <i>et al.</i> (2006) Eur. J. Pharmacol. 539:64-70
L109		Beyreuther <i>et al.</i> (2007) CNS Drug Rev. 13(1):21-42
L110		Beyreuther <i>et al.</i> (2007) Arthritis Res. Therapy 9:R14, http://arthritis-research.com/content/9/1/R14
L111		Bialer <i>et al.</i> (2001) Epilepsy Res. 43:11-58
L112		Bialer <i>et al.</i> (2002) Epilepsy Res. 51:31-71
L113		Bilsky <i>et al.</i> (2000) J. Med. Chem. 43:2586-2590
L114		Biton <i>et al.</i> (2003) Epilepsia 44(Suppl. 9):259, abst. 2.241 (copy of poster attached)
L115		Biton <i>et al.</i> (2004) "Safety and tolerability of lacosamide solution for infusion" Poster presented at AES Scientific Exhibit, December 3-7, 2004

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 6 of 12	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
L116		Biton <i>et al.</i> (2005) "Safety and tolerability of intravenous lacosamide as replacement for oral lacosamide in subjects with partial seizures" Poster P02.148 presented at International Epilepsy Congress, August 28 – September 1, 2005
L117		Biton (2006) "Multicenter, double-blind, double-dummy trial investigating safety, tolerability and pharmacokinetics of intravenous lacosamide (SPM 927) in subjects with partial seizures" Presented at European Congress on Epileptology 2006
L118		Blackburn-Munro <i>et al.</i> (2002) Eur. J. Pharmacol. 445:231–238
L119		Blair & Bean (2002) J. Neurosci. 22(23):10277–10290
L120		Blair & Bean (2003) J. Neurosci. 23(32):10338–10350
L121		Bolay <i>et al.</i> , (2002) "Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine". Nat. Med. 8:136-42
L122		Bretschneider <i>et al.</i> (2006) http://www.ampainsoc.org/db2/abstract/view?poster_id=2765#766
L123		Brodie (1996) Can. J. Neurol. Sci. 23(Suppl. 2):S6–S9
L124		Bunney & Garland (1982) Pharmacopsychiat. 15:111–115
L125		Caliendo <i>et al.</i> (2005) Curr. Med. Chem. 12(15):1721–1753
L126		Calvino <i>et al.</i> (1987) Behavioural Brain Res. 24:11–29
L127		Casey <i>et al.</i> (2003) Neuropsychopharmacol. 28:182–192
L128		Cawello <i>et al.</i> (2003) Epilepsia 44(Suppl. 9):95, abst. 1.265 (copy of poster attached)
L129		Cawello <i>et al.</i> (2004) Epilepsia 45(Suppl. 7):307, abst. 2.342 (copy of poster attached)
L130		Chen & Lipton (2006) J. Neurochem. 97:1611–1626
L131		Chevrier <i>et al.</i> (2004) Br. J. Pharmacol. 142:576–584
L132		Christensen <i>et al.</i> (1996) Pain 68:97–107
L133		Citrome (2003) Psychopharmacol. Bull. 37(Suppl. 2):74–88
L134		Colpaert <i>et al.</i> (1982) Life Sciences 31:67–75
L135		Cummins <i>et al.</i> (2004) J. Neurosci. 24(38):8232–8236
L136		Daniels <i>et al.</i> (2005) "Long-term safety and efficacy of lacosamide as adjunctive therapy in subjects with partial seizures: 96-week follow-up" Poster presented at AES Scientific Exhibit, December 2–5, 2005
L137		Decosterd & Woolf (2000) Pain 87:149–158
L138		Doty <i>et al.</i> (2004) in Bialer <i>et al.</i> , Epilepsy Res. 61:1–48, pp. 14–16

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 7 of 12	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
L139		Doty <i>et al.</i> (2004) "Update on the clinical development of SPM 927 (formerly harkoseride)" Presented at EILAT VII, May 2004
L140		Dowdall <i>et al.</i> (2005) Pharmacol. Biochem. Behavior 80:93-108
L141		Dubuisson & Dennis (1977) Pain 4:161-174
L142		Duncan & Kohn (2005) Epilepsy Res. 67:81-87
L143		Eller <i>et al.</i> (2005) Neurosurg. Focus 18(5):E3, 3 pp.
L144		Elliott (1997) Brain Res. 754:221-226
L145		Erichsen & Blackburn-Munro (2002) Pain 98:151-161
L146		Errington <i>et al.</i> (2005) "Lacosamide has a unique molecular mode of action" Poster presented at AES Scientific Exhibit, December 2-5, 2005
L147		Everill <i>et al.</i> (2001) Neurosci. 106(1):161-169
L148		Field <i>et al.</i> (1997) Br. J. Pharmacol. 121:1513-1522
L149		Field <i>et al.</i> (2002) J. Pharmacol. Exp. Ther. 303(2):730-735
L150		Fountain <i>et al.</i> (2000) Epilepsia 41(Suppl. 7):169 (copy of presentation attached)
L151		Freyenhagen <i>et al.</i> (2005) Pain 115:254-263
L152		Grippio <i>et al.</i> (2005) Psychopharmacol. 179:769-780
L153		Hama <i>et al.</i> (1999) Pharmacol. Biochem. Behavior 62:67-74
L154		Han <i>et al.</i> (2000) Pain 84:253-261
L155		Hao <i>et al.</i> (2004) "SPM 927, a new anti-epileptic drug, alleviates neuropathic pain-like behaviors in rats after spinal cord or trigeminal nerve injury" Poster presented at Neuropathic Pain - Changing Paradigms in Diagnosis and Treatment, Madrid, May 2004
L156		Heers <i>et al.</i> (2006) "The preclinical profile of the novel anticonvulsant lacosamide" Poster presented at European Congress on Epileptology 2006
L157		Henriksson (1999) Baillière's Clin. Rheumatol. 13(3):455-461
L158		Hidvegi <i>et al.</i> (2006) "Lacosamide in subjects with painful distal diabetic neuropathy: results of a multi-center, open-label, follow-on trial" Poster presented at American Pain Society, May 3-6, 2006
L159		Hofmann <i>et al.</i> (2003) Eur. J. Pharmacol. 470:17-25
L160		Holmberg <i>et al.</i> (2004) J. Med. Chem. 47:3927-3930
L161		Hong <i>et al.</i> (2004) J. Biol. Chem. 279(28):29341-29350

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 8 of 12	ATTORNEY DOCKET NO.	SERIAL No.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
L162		Honore <i>et al.</i> (2000) <i>Neurosci.</i> 98(3):585-598
L163		Horstmann <i>et al.</i> (2002) <i>Epilepsia</i> 43(Suppl. 7):188, abst. 2.174 (copy of poster attached)
L164		Horstmann <i>et al.</i> (2003) <i>Epilepsia</i> 44(Suppl. 9):97, Abst. 1.271 (copy of poster attached)
L165		Horstmann <i>et al.</i> (2003) "SPM 927 does not prolong the QTc interval" Poster presented at 6th International Conference on the Mechanisms and Treatment of Neuropathic Pain, San Francisco, Sep 18-20, 2003
L166		Hovinga (2003) <i>IDrugs</i> 6(5):479-485
L167		Hunskaar <i>et al.</i> (1985) <i>J. Neurosci. Methods</i> 14:69-76
L168		Hunt (2003) <i>Clin. Orthopaedics Rel. Res.</i> 409:96-105
L169		Hurley <i>et al.</i> (2002) <i>Anesthesiology</i> 97:1263-1273
L170		Ilyin <i>et al.</i> (2005) <i>Br. J. Pharmacol.</i> 144:801-812
L171		Jain (2000) <i>Emerging Drugs</i> 5(2):241-257
L172		Jensen (2000) <i>Eur. J. Neurol.</i> 7(Suppl. 3):3-4, abst. MT-9
L173		Kalso (2005) <i>Curr. Pharm. Design</i> 11:3005-3011
L174		Kemp & McKernan (2002) <i>Nature Neurosci. Suppl.</i> 5:1039-1042
L175		Kenney <i>et al.</i> (2006) http://www.ampainsoc.org/db2/abstract/view?poster_id=2773#774
L176		Kim & Chung (1992) <i>Pain</i> 50(3):355-363
L177		Kropeit <i>et al.</i> (2004) <i>Epilepsia</i> 45(Suppl. 7): 123, abst. 1.323 (copy of poster attached)
L178		Kropeit <i>et al.</i> (2005) "Low drug-interaction potential of Lacosamide" Poster 702 presented at American Pain Society 2005 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster_id=2394#702)
L179		Kropeit <i>et al.</i> (2006) "Lacosamide has low potential for drug-drug-interaction" Poster 851 presented at American Pain Society 2006 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster_id=2848#851)
L180		Lai <i>et al.</i> (2003) <i>Curr. Opin. Neurobiol.</i> 13:291-297
L181		Lai <i>et al.</i> (2004) <i>Ann. Rev. Pharmacol. Toxicol.</i> 44:371-397
L180		Lampert <i>et al.</i> (2006) <i>Exp. Brain Res.</i> 174(4):660-666
L183		Lawand <i>et al.</i> (1997) <i>Eur. J. Pharmacol.</i> 324:169-177
L184		Leao AAP (1994) "Spreading depression of activity in the cerebral cortex". <i>J. Neurophysiol.</i> 7:359-390.
L185		Lee <i>et al.</i> (2000) <i>NeuroReport</i> 11(4):657 - 661

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 9 of 12	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
L186		Lee <i>et al.</i> (2002) J. Biol. Chem. 277(8):6542-6549
L187		Lesser <i>et al.</i> (2004) Neurology 63:2104-2110
L188		LeTiran <i>et al.</i> (2002) J. Med. Chem. 45:4762-4773
L189		Lockwood <i>et al.</i> (2002) N. Engl. J. Med. 347(12):904-910
L190		Lu & Westlund (1999) J. Pharmacol. Exp. Ther. 290:214-219
L191		Lynch <i>et al.</i> (2004) Pain 110:56-63
L192		Mach <i>et al.</i> (2002) Neurosci. 113(1):155-166
L193		Macres (2000) "Understanding neuropathic pain" http://www.spineuniverse.com/displayarticle.php/article1614.html
L194		Maier <i>et al.</i> (2004) "A pilot randomized, double-blind, placebo-controlled pilot trial to investigate safety and efficacy of SPM 927 in subjects with postherpetic neuralgia" Poster presented at Neuropathic Pain, May 13-14, 2004
L195		Majumdar <i>et al.</i> (2004) Eur. J. Neurosci. 20:127-143
L196		March (1985) Advanced Organic Chemistry, New York: Wiley, pp. 16-18
L197		McCleane (2003) CNS Drugs 17(14):1031-1043
L198		McCleane <i>et al.</i> (2003) Neurosci. Lett. 352:117-120
L199		Meinardi (1995) in Levy <i>et al.</i> , ed. "Antiepileptic Drugs", 4th ed., chap. 6, pp. 91-97; New York: Raven Press
L200		Mohapatra <i>et al.</i> (2003) Mol. Cell. Neurosci. 23:314-324
L201		Moller (2000) J. Am. Acad. Audiol. 11(3):115-124
L202		Morrow <i>et al.</i> (2001) Soc. Neurosci. Conf. Abst. 508
L203		Morrow <i>et al.</i> (2003) "The effects of lacosamide in animal models for acute, inflammatory and neuropathic pain" Poster presented at AES Scientific Exhibit, December 5-10, 2003
L204		Nakata <i>et al.</i> (2003) Biol. Psychiatry 53:571-576
L205		Papapetropoulos & Singer (2007) Seminars in Neurology 27(2):183-194
L206		Patel <i>et al.</i> (2001) Pain 90:217-226
L207		Pessoa-Mahana <i>et al.</i> (2003) Mini Rev. Med. Chem. 3:77-93
L208		Priestley (2004) Curr. Drug Targets - CNS & Neurol. Disorders 3:441-456
L209		Randall & Selitto (1957) Arch. Int. Pharmacodyn. 91:409-419

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 10 of 12	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
L210		Rauck <i>et al.</i> (2003) "A randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of SPM 927 in painful diabetic neuropathy" Poster presented at 6th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, Sep 2003
L211		Rauck <i>et al.</i> (2007) Clin. J. Pain 23(2):150-158
L212		Rauschkolb <i>et al.</i> (2004) "SPM 927, a novel promising pain treatment" Presented at Visiongain Pain Management, 2004
L213		Remy <i>et al.</i> (2004) Neuropharmacol. 47:1102-1112
L214		Richeimer (2000) "The Richeimer Pain Update" http://www.helpforpain.com/arch2000dec.htm
L215		Rodger (1991) Can. Med. Assoc. J. 145:1571-1581
L216		Rosenfeld <i>et al.</i> (2003) Epilepsia 44(Suppl. 9):262, abst. 2.249 (copy of poster attached)
L217		Rosenfeld <i>et al.</i> (2005) Epilepsia 46(Suppl. 8):184, abst. 2.278 (copy of poster attached)
L218		Rosenstock <i>et al.</i> (2004) Pain 110:628-638
L219		Rüttiger <i>et al.</i> (2003) Hear. Res. 180:39-50
L220		Sachdeo <i>et al.</i> (2003) "An open-label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures" Poster presented at 55th Annual Meeting, American Academy of Neurology, March 2003
L221		Saddi & Abbott (2000) Pain 89:53-63
L222		Schiltmeyer <i>et al.</i> (2004) Epilepsia 45(Suppl. 7):313, abst. 2.361 (copy of poster attached)
L223		Schiltmeyer <i>et al.</i> (2006) "No interaction between lacosamide and metformin" Poster 850 presented at American Pain Society 2006 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster_id=2847#850)
L224		Seltzer <i>et al.</i> (2001) Pain 93:101-106
L225		Shaibani <i>et al.</i> (2005) "An open-label follow-on trial to assess the long-term safety and efficacy of oral lacosamide in subjects with diabetic neuropathy" Poster presented at World Congress on Pain, August 21-26, 2005
L226		Shiro <i>et al.</i> (1996) Psychiatry Clin. Neurosci. 50:141-146
L227		Silver & Soderlund (2005) Neurotoxicol. 26:397-406
L228		Sindrup & Jensen (1999) Pain 83:389-400
L229		Sommerville (2003) "Schwarz Pharma's Neurology Pipeline" http://www.schwarzpharma.com/uploads/assets/1369_4_neurology_KNS_190203.pdf

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 11 of 12	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
L230		Sommerville & Whitesides (2004) "Intravenous SPM 927 (formerly harkoseride)" Presented at EILAT VII, May 2004
L231		Stein <i>et al.</i> (1988) Pharmacol. Biochem. Behavior 31:445-451
L232		Stoehr <i>et al.</i> (2005) "Lacosamide displays potent antinociceptive effects in animal models for neuropathic and inflammatory pain" Poster presented at World Congress on Pain, August 21-26, 2005
L233		Stoehr & Beyreuther (2005) "The effect of lacosamide in comparison to other analgesics in rat models for neuropathic pain" Poster presented at 8th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, San Francisco, November 3-5, 2005
L234		Stoehr <i>et al.</i> (2006) Eur. J. Pain 10:241-249
L236		Teng & Abbott (1998) Pain 76:337-347
L236		Tjølsen (1992) Pain 51:5-17
L237		Tjølsen & Hole (1997) in Dickinson & Besson, ed., "The Pharmacology of Pain", chap. 1, pp. 1-20; Berlin: Springer-Verlag
L238		Vaiciene <i>et al.</i> (2006) "Multicenter, open-label trial investigating safety and tolerability of intravenous lacosamide (SPM 927) as replacement for oral lacosamide in subjects with partial seizures: report of first cohort" Poster presented at European Congress on Epileptology 2006
L239		Vos <i>et al.</i> (1994) J. Neurosci. 14(5):2708-2723
L240		Watson <i>et al.</i> (1997) Pain 70:53-58
L241		Wheeler-Aceto <i>et al.</i> (1990) Pain 40:229-238
L242		Wheeler-Aceto & Cowan (1991) Psychopharmacol. 104:35-44
L243		Whitesides <i>et al.</i> (2004) "Long-term safety and efficacy of lacosamide as adjunctive therapy in subjects with partial seizures: 48-week follow-up" Poster presented at AES Scientific Exhibit, December 3-7, 2004
L244		Wood <i>et al.</i> (2002) in "Sodium Channels and Neuronal Hyperexcitability", pp. 159-172; Chichester: Wiley
L245		Wood <i>et al.</i> (2004) J. Neurobiol. 61:55-71
L246		Wu <i>et al.</i> (2005) J. Physiol. 565.2:371-380
L247		Wymer <i>et al.</i> (2005) "A multi-center, randomized double-blind, placebo-controlled trial to assess the efficacy and safety of lacosamide in subjects with painful distal diabetic neuropathy." 8th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, San Francisco, Nov 3-5, 2005
L248		Xu <i>et al.</i> (1992) Pain 48(2):279-290 (abstract only)
L249		Yezierski <i>et al.</i> (1998) Pain 75:141-155

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 12 of 12</p>	ATTORNEY DOCKET NO.	SERIAL No.
	6102-000049/US/NP	10/599,976
	APPLICANT	
	Scheller, D. & Stoehr, T.	
	FILING DATE	GROUP
	October 16, 2006	1614

OTHER DOCUMENTS		
Ref. Desig.	Examiner's Initials	
L250		Ziegler <i>et al.</i> (2005) "Efficacy and safety of lacosamide in the treatment of neuropathic pain attributed to distal diabetic neuropathy." 8th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, San Francisco, November 3-5, 2005

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner: /Marcela Cordero Garcia/	Date Considered: 02/28/2010
------------------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.